Humoral response against spike protein enhanced by fifth and sixth COVID-19 mRNA vaccine in the uninfected and infected subjects

References

• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–5. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Kato H, Miyakawa K, Ohtake N, Yamaoka Y, Yajima S, Yamazaki E, Shimada T, Goto A, Nakajima H, Ryo A, et al. Vaccine-induced humoral response against SARS-CoV-2 dramatically declined but cellular immunity possibly remained at 6 months post BNT162b2 vaccination. Vaccine. 2022;40(19):2652–5. doi:10.1016/j.vaccine.2022.03.057.
   PubMed Web of Science ®Google Scholar
• Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y, Bowen AD, Liu M, Wang M, Yu J, et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2023;186(2):279–86.e8. doi:10.1016/j.cell.2022.12.018.
   PubMed Web of Science ®Google Scholar
• Tan ST, Kwan AT, Rodríguez-Barraquer I, Singer BJ, Park HJ, Lewnard JA, Sears D, Lo NC. Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave. Nat Med. 2023;29:358–65. doi:10.1038/s41591-022-02138-x.
   PubMed Web of Science ®Google Scholar
• Magen O, Waxman JG, Makov-Assif M, Vered R, Dicker D, Hernán MA, Lipsitch M, Reis BY, Balicer RD, Dagan N, et al. Fourth dose of BNT162b2 mRNA COVID-19 vaccine in a nationwide setting. N Engl J Med. 2022;386(17):1603–14. doi:10.1056/NEJMoa2201688.
   PubMed Web of Science ®Google Scholar
• Prime minister’s Office of Japan. COVID-19 vaccines. [accessed 2023 Sept 7]. https://www.kantei.go.jp/jp/headline/kansensho/vaccine_supply.html.
   Google Scholar
• Ministry of Health Labour and Welfare. Survey of COVID-19 antibody prevalence using blood donation samples. [accessed 2023 Sep 7]. https://www.mhlw.go.jp/content/10906000/001070846.pdf.
   Google Scholar
• Krutikov M, Palmer T, Tut G, Fuller C, Azmi B, Giddings R, Shrotri M, Kaur N, Sylla P, Lancaster T, et al. Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England. Lancet Heal Longev. 2022;3:e13–e21. doi:10.1016/S2666-7568(21)00282-8.
   PubMedGoogle Scholar
• Burbelo PD, Riedo FX, Morishima C, Rawlings S, Smith D, Das S, Strich JR, Chertow DS, Davey RT, Cohen JI, et al. Sensitivity in detection of antibodies to nucleocapsid and spike proteins of severe acute respiratory syndrome coronavirus 2 in patients with coronavirus disease 2019. J Infect Dis. 2020;222(2):206–13. doi:10.1093/infdis/jiaa273.
   PubMed Web of Science ®Google Scholar
• Kato H, Miyakawa K, Ohtake N, Go H, Yamaoka Y, Yajima S, Shimada T, Goto A, Nakajima H, Ryo A, et al. Antibody titers against the alpha, beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay. J Infect Chemother. 2022;28(2):273–8. doi:10.1016/j.jiac.2021.11.021.
   PubMed Web of Science ®Google Scholar
• Goto A, Miyakawa K, Nakayama I, Yagome S, Xu J, Kaneko M, Ohtake N, Kato H, Ryo A. Prediction models for neutralization activity against emerging SARS-CoV-2 variants: a cross-sectional study. Front Microbiol. 2023;14:1126527. doi:10.3389/fmicb.2023.1126527.
   PubMed Web of Science ®Google Scholar
• Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C, Selemon A, Whelan M, Premji Z, Issa H, et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the Omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect Dis. 2023;23(5):556–67. doi:10.1016/S1473-3099(22)00801-5.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. Decades in the making: mRNA COVID-19 vaccines. [accessed 2023 Sep 7]. https://covid19.nih.gov/nih-strategic-response-covid-19/decades-making-mrna-covid-19-vaccines.
   Google Scholar
• Regev-Yochay G, Gonen T, Gilboa M, Mandelboim M, Indenbaum V, Amit S, Meltzer L, Asraf K, Cohen C, Fluss R, et al. Efficacy of a fourth dose of COVID-19 mRNA vaccine against Omicron. N Engl J Med. 2022;386(14):1377–80. doi:10.1056/NEJMc2202542.
   PubMed Web of Science ®Google Scholar
• Grewal R, Kitchen SA, Nguyen L, Buchan SA, Wilson SE, Costa AP, Kwong JC. Effectiveness of a fourth dose of COVID-19 mRNA vaccine against the Omicron variant among long term care residents in Ontario, Canada: test negative design study. BMJ. 2022;378:e071502. doi:10.1136/bmj-2022-071502.
   PubMedGoogle Scholar
• Nordström P, Ballin M, Nordström A. Effectiveness of a fourth dose of mRNA COVID-19 vaccine against all-cause mortality in long-term care facility residents and in the oldest old: a nationwide, retrospective cohort study in Sweden. Lancet Reg Heal Eur. 2022;21:100466. doi:10.1016/j.lanepe.2022.100466.
   PubMedGoogle Scholar
• Tani Y, Takita M, Wakui M, Saito H, Nishiuchi T, Zhao T, Yamamoto C, Kawamura T, Sugiyama A, Nakayama A, et al. Five doses of the mRNA vaccination potentially suppress ancestral-strain stimulated SARS-CoV2-specific cellular immunity: a cohort study from the Fukushima vaccination community survey, Japan. Front Immunol. 2023;14:1240425. doi:10.3389/fimmu.2023.1240425.
   PubMed Web of Science ®Google Scholar
• van Gemert J, Steenberg F, van Leer-Buter C, Kerstjens H, Steenhuis W, Akkerman O, Verschuuren E, Gan T. Increasing antibody responses to five doses of SARS-CoV-2 mRNA vaccine in lung transplant patients. J Clin Med. 2023;12:12. doi:10.3390/jcm12124125.
   Web of Science ®Google Scholar
• Ma KC, Dorabawila V, León TM, Henry H, Johnson AG, Rosenberg E, Mansfield JA, Midgley CM, Plumb ID, Aiken J, et al. Trends in laboratory-confirmed SARS-CoV-2 reinfections and associated hospitalizations and deaths among adults aged ≥18 years — 18 U.S. Jurisdictions, September 2021–December 2022. Morb Mortal Wkly Rep. 2023;72:683–9. doi:10.15585/mmwr.mm7225a3.
   PubMedGoogle Scholar
• Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med. 2022;28(11):2398–405. doi:10.1038/s41591-022-02051-3.
   PubMed Web of Science ®Google Scholar
• Swartz MD, DeSantis SM, Yaseen A, Brito FA, Valerio-Shewmaker MA, Messiah SE, Leon-Novelo LG, Kohl HW, Pinzon-Gomez CL, Hao T, et al. Antibody duration after infection from SARS-CoV-2 in the Texas coronavirus antibody response survey. J Infect Dis. 2023;227(2):193–201. doi:10.1093/infdis/jiac167.
   PubMed Web of Science ®Google Scholar
• Ma Q, Liu J, Liu Q, Kang L, Liu R, Jing W, Wu Y, Liu M. Global percentage of asymptomatic SARS-CoV-2 infections among the tested population and individuals with confirmed COVID-19 diagnosis: a systematic review and meta-analysis. JAMA Netw Open. 2021;4:e2137257. doi:10.1001/jamanetworkopen.2021.37257.
   PubMed Web of Science ®Google Scholar
• Hibino M, Watanabe S, Kamada R, Tobe S, Maeda K, Horiuchi S, Kondo T. Antibody responses to the BNT162b2 mRNA vaccine in healthcare workers in a general Hospital in Japan: a comparison of two assays for anti-spike protein immunoglobulin G. Intern Med. 2022;61:811–9. doi:10.2169/internalmedicine.8704-21.
   PubMed Web of Science ®Google Scholar
• Higashimoto Y, Kozawa K, Miura H, Kawamura Y, Ihira M, Hiramatsu H, Suzuki R, Haga K, Takai-Todaka R, Sawada A, et al. Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients. Hum Vaccin Immunother. 2022;18(6):2105611. doi:10.1080/21645515.2022.2105611.
   PubMed Web of Science ®Google Scholar